Cyclin-Dependent Kinase 11A (CDK11A) (AA 5-216) Antikörper (HRP)

Produktnummer ABIN7148850

Produktdetails

Target: Cyclin-Dependent Kinase 11A (CDK11A)

Bindungsspezifität: AA 5-216

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: HRP

Applikation: ELISA

Kreuzreaktivität: Human

Aufreinigung: >95%, Protein G purified

Immunogen: Recombinant Human Cyclin-dependent kinase 11A protein (5-216AA)

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Antigendetails

Target: Cyclin-Dependent Kinase 11A (CDK11A)

Andere Bezeichnung: CDK11A (CDK11A Produkte)

Synonyme: CDC2L2 antikoerper, CDC2L3 antikoerper, CDK11-p110 antikoerper, CDK11-p46 antikoerper, CDK11-p58 antikoerper, PITSLRE antikoerper, p58GTA antikoerper, CDC2L1 antikoerper, cPITSLRE antikoerper, cyclin dependent kinase 11A antikoerper, cyclin-dependent kinase 11A antikoerper, CDK11A antikoerper, LOC100338292 antikoerper

Hintergrund: CD11A_HUMAN antibody, CDC2L2 antibody, CDC2L3 antibody, CDK11 antibody, CDK11 p110 antibody, CDK11 p46 antibody, CDK11 p58 antibody, CDK11A antibody, Cell division cycle 2 like 2 (PITSLRE proteins) antibody, Cell division cycle 2-like protein kinase 2 antibody, Cell division protein kinase 11A antibody, Cyclin-dependent kinase 11A antibody, Galactosyltransferase-associated protein kinase p58/GTA antibody, p58GTA antibody, PITSLRE antibody, PITSLRE B antibody, PITSLRE protein kinase beta antibody, PITSLRE serine/threonine-protein kinase CDC2L2 antibody, PITSLREB antibody

UniProt: Q9UQ88

Pathways: M Phase